A Study on the Peripheral Blood in Patients With Acute Coronary Syndrome

NCT06955143 · tracked via the Priya Life Science China tracker

Sponsor

Second Affiliated Hospital of Wenzhou Medical University

Phase

Observational

Started

2025-03-11

Last updated

2025-07-25

Condition(s) studied

Acute Coronary SyndromeChronic Coronary Syndrome

Study summary

The goal of this study is to conduct analyses the changes of cell growth factors, inflammatory factors, metabolites, plasma proteome, etc. in the blood of patients with ACS (acute coronary syndrome), as well as their correlations with the disease prognosis, based on multi-omics or other related research methods. The main questions it aims to answer are:

The growth factors that have significant changes in the peripheral blood of the ACS population, especially fibroblast growth factors? Inflammatory factors and chemokines related to the onset of ACS? The metabolites and proteins that are significantly altered in the peripheral blood after the onset of ACS? Researchers will compare ACS population to CCS (Chronic Coronary Syndrome) population, and control group (patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy).The peripheral venous blood from the participants will be collected within 24 hours after their admission to the hospital.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: For ACS group STEMI * cTn\>99th ULN or CK-MB\>99th ULN * ST-segment elevation with a convex upward morphology * in conjunction with one or more of the following conditions: persistent ischemic chest pain; echocardiographic evidence of abnormal segmental ventricular wall motion; or abnormal coronary angiography findings. NSTEMI * cTn\>99th ULN or CK-MB\>99th ULN * accompanied by one or more of the following situations: persistent ischemic chest pain; new ST-segment depression or low and inverted T waves; echocardiography showing segmental ventricular wall motion abnormalities; abnormal coronary angiography. UA * cTn normal * ischemic chest pain with an electrocardiogram showing transient ST-segment depression or flattened and inverted T waves * evidence of coronary artery stenosis (e.g., CTA demonstrating ≥ 50% stenosis) For CCS group * Clinical Diagnosis Consistent with CCS Categories, meet any one of the following clinical scenarios: Stable Angina Pectoris, Ischemic Cardiomyopathy, Post-ACS Stable Phase, Long-Term CAD Management, Vasospastic or Microvascular Disease, Asymptomatic CAD * Laboratory and Imaging Confirmation: Resting ECG without ST-segment elevation or dynamic changes (excluding ACS), cTn normal or stable (no acute myocardial injury), ≥50% luminal stenosis in ≥1 epicardial coronary artery For control group * Patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy Exclusion Criteria: * Lactating or pregnant women * Patients with malignant neoplasms * Severe hepatic/renal dysfunction * Severe hematological disorders * Autoimmune diseases

Primary outcome measure(s)

circulating fibroblast growth factors (FGFs) levels — within 24 hours of admission to the hospital
examining the circulating fibroblast growth factors levels in the peripheral venous blood of the participants
circulating inflammatory cytokines levels — within 24 hours of admission to the hospital
examining the circulating inflammatory cytokines levels in the peripheral venous blood of the participants
circulating chemokines levels — within 24 hours of admission to the hospital
examining the circulating chemokines levels in the peripheral venous blood of the participants
circulating Cytochrome C level — within 24 hours of admission to the hospita
examining the circulating cytochrome c levels in the peripheral venous blood of the participants
circulating mitochondrial DNA levels — within 24 hours of admission to the hospital
examining the circulating mitochondrial DNA levels in the peripheral venous blood of the participants
circulating malondialdehyde levels — within 24 hours of admission to the hospital
examining the circulating malondialdehyde levels in the peripheral venous blood of the participants

Trial sites (1)

Facility	City	Region	Status
Lishui Central Hospital	Lishui	Zhejiang	Recruiting

More Second Affiliated Hospital of Wenzhou Medical University trials in China

Effect of FPCA on Incidence of Emergency Delirium in Children After Surgery Recruiting

Effect of Bright Light Therapy on Idiopathic Scoliosis Recruiting

Effect of Sevoflurane on Sweat Threshold in Children of Different Ages Starting soon

A Real-World Exploratory Study on the Sleep-Improving Efficacy of Dong'e Brand Ejiao Yuanjiang Active, not recruiting

Gastric Cancer Marker Detection and Its Kit Development Recruiting

Other trials for the same condition

Use of Determine Learning-based Cardiodynamicsgram (CDG) for Rapid and Precise Stratification of Chest Pain in Emergency Department Recruiting

NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI Recruiting

Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol Starting soon

Magnetocardiography in the Accurate Identification of Myocardial Infarction Recruiting

OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06955143 on ClinicalTrials.gov ↗ ← All trials in China